Results 31 to 40 of about 6,619 (182)

Effectiveness of Tolvaptan Treatment in Hyponatremic Patients

open access: yesTurkish Journal of Internal Medicine, 2020
Objective: Non-peptide vasopressin receptor antagonists (vaptans) are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients.
Mehmet Fethullah Aydın   +4 more
doaj   +1 more source

Tolvaptan and urea in paediatric hyponatraemia [PDF]

open access: yes, 2023
BACKGROUND: The syndrome of inappropriate antidiuretic hormone (SIADH) is usually treated with fluid restriction. This can be challenging in patients with obligate fluid intake for nutrition or medication. Pharmaceutical treatment with tolvaptan and urea
Amin, Rakesh   +9 more
core   +1 more source

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis

open access: yesNefrología (English Edition), 2023
Background: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan.
Xuanwei Li   +4 more
doaj   +3 more sources

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

open access: yesKidney Diseases, 2021
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide.
Fei Liu   +4 more
doaj   +1 more source

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations [PDF]

open access: yes, 2018
Laia Sans-Atxer,1 Dominique Joly2 1Department of Nephrology, Hospital del Mar, Institut Mar for Medical Research, Barcelona, Spain; 2Faculty of Medicine, Université Paris-Descartes, Assistance Publique-Hôpitaux de Paris, Service de Né ...
Joly D   +5 more
core   +1 more source

Tolvaptan in ADPKD Patients With Very Low Kidney Function [PDF]

open access: yes, 2021
Introduction: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials.
Lee, Jennifer   +17 more
core   +1 more source

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

open access: yesPharmacology Research & Perspectives, 2023
The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with ...
Takahiro Kato   +7 more
doaj   +1 more source

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

open access: yesPatient Preference and Adherence, 2021
Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H   +3 more
doaj  

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury

open access: yes, 2020
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients.
Mosedale, Merrie   +5 more
core   +1 more source

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure

open access: yesESC Heart Failure, 2020
Aims Although tolvaptan has been reported to prevent worsening renal function (WRF) in patients with advanced acute heart failure (AHF), evidence regarding the effect of tolvaptan on renal function in patients with new‐onset AHF is not available.
Hiromi Kin   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy